Get the Stockscreener App
15.67
1.16%
0.18
Overview
News
Price History
Option Chain
Why RDY Down?
Discussions
Forecast
Stock Split
Dividend History
Dr Reddys Laboratories Ltd Adr stock is traded at $15.67, with a volume of 493.65K.
It is up +1.16% in the last 24 hours and up +10.35% over the past month.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
See More
Previous Close:
$15.49
Open:
$15.55
24h Volume:
493.65K
Relative Volume:
0.50
Market Cap:
$13.00B
Revenue:
$3.47B
Net Income/Loss:
$668.83M
P/E Ratio:
4.2194
EPS:
3.7138
Net Cash Flow:
$253.46M
1W Performance:
+8.22%
1M Performance:
+10.35%
6M Performance:
+8.68%
1Y Performance:
+16.37%
1-Day Range:
$15.52
$15.69
1-Week Range:
$14.53
$15.69
52-Week Range:
$13.41
$16.89
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Compare RDY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
15.66 | 13.00B | 3.47B | 668.83M | 253.46M | 4.0127 |
|
ZTS
Zoetis Inc
|
164.70 | 74.13B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.745 | 43.93B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.16 | 41.58B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.25 | 25.41B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.38 | 14.57B | 15.05B | -883.30M | 1.89B | -0.74 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Nomura | Buy → Neutral |
| Jan-11-24 | Downgrade | Jefferies | Buy → Underperform |
| Aug-29-23 | Downgrade | HSBC Securities | Buy → Hold |
| May-18-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-17-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-30-23 | Initiated | JP Morgan | Underweight |
| Nov-14-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-03-22 | Resumed | BofA Securities | Neutral |
| Jul-27-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Feb-02-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-18-20 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-18-20 | Upgrade | Investec | Sell → Hold |
| Jan-28-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-27-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-09-20 | Upgrade | Citigroup | Sell → Buy |
| Nov-04-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Sep-04-19 | Upgrade | Credit Suisse | Underperform → Outperform |
| Jul-01-19 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-20-19 | Initiated | Deutsche Bank | Hold |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-20-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-19-19 | Upgrade | CLSA | Outperform → Buy |
| Jan-17-19 | Downgrade | Citigroup | Neutral → Sell |
| Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-31-17 | Upgrade | CLSA | Underperform → Outperform |
| Jul-28-17 | Downgrade | CLSA | Underperform → Sell |
| Jul-27-16 | Downgrade | HSBC Securities | Hold → Reduce |
| Jul-27-16 | Downgrade | Jefferies | Hold → Underperform |
| Feb-10-16 | Upgrade | Credit Agricole | Underperform → Buy |
| Nov-10-15 | Downgrade | Citigroup | Buy → Neutral |
View All
Dr Reddys Laboratories Ltd Adr Stock (RDY) Latest News
Weekly Upgrades and Downgrades - InvestorPlace
Stock Market News Today Live Updates on December 20, 2024 : Top Gainers and Losers today on 20 December, 2024: Dr Reddys Laboratories, ICICI Bank, Tech Mahindra, Trent among most active stocks; Check full list here | Stock Market News - Mint
Coccidioidomycosis Drugs Market to Reach US$ 634.3 Million by 2034, Expanding at a CAGR of 4.9% | Fact.MR Report - GlobeNewswire Inc.
Teva Pharmaceutical ADR Gets Relative Strength Rating Upgrade - Investor's Business Daily
ADR, GDR Listings of Indian companies - Goodreturns
Asian Equities Traded in the US as American Depositary Receipts Edge Down in Wednesday Trading - MSN
NVO Stock Quote Price and Forecast - CNN
(PDF) The impact of Clinical Pharmacist Lead Collaborative Care on Quality Of Life of the Patients with Bipolar Disorder: A Unicenter Prospective, Randomization Study - ResearchGate
Asian Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading - MSN
Asian Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading - MSN
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - MSN
Jharkhand Elections Phase 2: Richest candidate declares assets worth Rs 402 cr – Check list of top 10 wealthiest candidates - The Financial Express
Jharkhand Phase 2 Elections 2024: 122 candidates with serious criminal cases get tickets, shows ADR report - The Financial Express
Dr. Reddy's Laboratories Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next - Simply Wall St
Earnings call: Dr. Reddy's reports robust growth and strategic expansions By Investing.com - Investing.com Australia
Earnings call: Dr. Reddy's reports robust growth and strategic expansions - Investing.com India
Dr. Reddy's stock poised for recovery with new US launches and global OTC gains—BofA - Investing.com India
Dr. Reddy's stock poised for recovery with new US launches and global OTC gains—BofA By Investing.com - Investing.com South Africa
Dr Reddy's Q2 Results: Revenue Rises 17% To Rs 8,106 Crore - Business Today
Dr. Reddy’s Labs ADR earnings missed by $0.85, revenue topped estimates - Investing.com Australia
Q2 results today: Titan, Dr Reddy's among 63 companies to announce earnings on Tuesday - The Economic Times
Dr Reddy’s Q2FY25 earnings preview: Expectations of steady revenue growth but margins under pressure - MSN
Dr Reddys Q2FY25 earnings preview: Expectations of steady revenue growth but margins under pressure - Zee Business
Asian Equities Traded in the US as American Depositary Receipts Climb Higher Friday - MSN
BP Faces Price Forecast Cuts As Analysts Flag Weak Earnings And Rising Debt Challenges - Yahoo Finance
Dr Reddy's Labs shares down 80% today? DRL stock turns ex-split - Business Today
Maharashtra: 93% MLAs crorepatis, 60% with criminal cases against them – know the composition of outgoing assembly | Mint - Mint
Saudi Arabia Heparin Market Size & Outlook, 2023-2030 - Grand View Research
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading - MSN
Indian stock market: 8 things that changed for market overnight- Gift Nifty, US retail sales, ECB rate cut to Q2 results | Stock Market News - Mint
Infosys, Wipro ADRs down 3% on NYSE after Q2 results even as S&P, Dow drift near record-highs | Stock Market News - Mint
Q2 Results Updates: Infosys ADR Falls Over 3%, Wipro Down Over 4% - NDTV Profit
Top gainers and losers for today on October 16: HDFC Life, Dr Reddy’s Labs, Grasim lead NIFTY movers - Upstox
1:5 Stock Split By Large-Cap Pharma Stock; Record DateOct 28: Buy Dr Reddy's For Rs 7,300 Target - Goodreturns
Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Saudi Arabia Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Haryana Election 2024: 95 candidates have serious criminal cases against them, 11 with cases of crime against women, says report - The Financial Express
Side-effects of banned drug Nimesulide still reported in children: Report | Today News - Mint
Dr. Reddy’s Announces Share Subdivision Date - TipRanks
Dr Reddy's, Hetero sign voluntary licenses with Gilead for HIV drug - Business Standard
Haryana Elections 2024: Capt. Abhimanyu, Savitri Jindal among wealthiest candidates for October 5 polls | Mint - Mint
Assam: Mobile internet services to be disabled for eight hours on Sunday, here's why | Today News - Mint
Apni Party's Altaf Bukhari, BJP's Devender Rana among 3 richest candidates in Jammu and Kashmir assembly poll fray | Mint - Mint
Dr. Reddy's Laboratories Share Price Today Live Updates: Dr. Reddy's Laboratories Sees Minor Price Dip A... - The Economic Times
Dr. Reddy’s Empowers Employees with Stock Options - TipRanks
Dr Reddys Laboratories Ltd Adr Stock (RDY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):